Ravi C Balijepalli Selected Research

Long QT Syndrome

1/2019	Long QT syndrome caveolin-3 mutations differentially modulate Kv 4 and Cav 1.2 channels to contribute to action potential prolongation.
8/2013	Caveolin-3 suppresses late sodium current by inhibiting nNOS-dependent S-nitrosylation of SCN5A.
12/2012	Mechanism of loss of Kv11.1 K+ current in mutant T421M-Kv11.1-expressing rat ventricular myocytes: interaction of trafficking and gating.
6/2010	Properties of WT and mutant hERG K(+) channels expressed in neonatal mouse cardiomyocytes.
10/2008	Caveolae, ion channels and cardiac arrhythmias.
11/2006	Mutant caveolin-3 induces persistent late sodium current and is associated with long-QT syndrome.
7/2005	Intragenic suppression of trafficking-defective KCNH2 channels associated with long QT syndrome.
9/2003	Thapsigargin selectively rescues the trafficking defective LQT2 channels G601S and F805C.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Ravi C Balijepalli Research Topics

Disease

8	Long QT Syndrome 01/2019 - 09/2003
4	Heart Failure 05/2011 - 07/2003
3	Cardiac Arrhythmias (Arrythmia) 01/2019 - 10/2008
3	Cardiomegaly (Heart Hypertrophy) 09/2015 - 11/2003
2	Dilated Cardiomyopathy (Cardiomyopathy, Congestive) 01/2012 - 07/2003
1	Hypertension (High Blood Pressure) 01/2023
1	Cardiovascular Diseases (Cardiovascular Disease) 11/2021
1	Ventricular Premature Complexes (Premature Ventricular Contraction) 03/2016
1	Cardiomyopathies (Cardiomyopathy) 03/2016
1	Sudden Infant Death (SID) 08/2013
1	congenital stationary Night blindness 05/2013
1	Colonic Neoplasms (Colon Cancer) 11/2012
1	Hypertrophy 05/2011
1	Heart Diseases (Heart Disease) 10/2008
1	Channelopathies 11/2006
1	Myocardial Ischemia (Ischemic Heart Diseases) 11/2003
1	Tachycardia (Tachyarrhythmias) 07/2003

Drug/Important Bio-Agent (IBA)

6	Caveolin 3IBA 01/2019 - 11/2006
5	Proteins (Proteins, Gene)FDA Link 01/2019 - 07/2003
4	Ether (Diethyl Ether)IBA 12/2012 - 09/2003
2	SodiumIBA 11/2016 - 11/2006
2	Ion Channels (Ion Channel)IBA 03/2016 - 10/2008
2	CaveolinsIBA 11/2012 - 05/2011
1	Biomarkers (Surrogate Marker)IBA 11/2021
1	Polyvinyl Chloride (PVC)IBA 03/2016
1	Protein Kinases (Protein Kinase)IBA 09/2015
1	CalcineurinIBA 09/2015
1	Protein Kinase CIBA 09/2015
1	Angiotensin IIIBA 09/2015
1	Calcium Channels (Calcium Channel)IBA 05/2013
1	Leucine (L-Leucine)FDA Link 01/2012
1	Natriuretic PeptidesIBA 05/2011
1	AnkyrinsIBA 11/2006
1	beta Adrenergic ReceptorsIBA 09/2005
1	Adrenergic Agents (Adrenergic Drugs)IBA 09/2005
1	Endothelin-1 (Endothelin 1)IBA 11/2003
1	Coloring Agents (Dyes)IBA 07/2003

Therapy/Procedure

1	Precision Medicine 01/2023
1	Chronotherapy 01/2023
1	Therapeutics 11/2016